Latest news with #Patience
Business Wire
3 days ago
- Business
- Business Wire
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the 'Company'), an oncology company integrating novel delivery technology with standard of care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of David B. Patience as Chief Financial Officer, effective July 1, 2025. Mr. Patience succeeds James Young, who stepped down for personal reasons effective May 30, 2025. Dan Giordano, Vice President of Finance for TriSalus, will serve as acting Chief Financial Officer during the transition period. Mr. Young remains available to the Company to support an orderly transition. 'We are thrilled to welcome David to our leadership team,' said Mary Szela, President and CEO of TriSalus Life Sciences. 'David's strong expertise in capital markets and proven track record of financial leadership and operational execution will be invaluable and play a crucial role as we drive our next phase of growth. On behalf of our leadership team, I also thank Jim Young for his service and contributions. We wish him the best in his future endeavors.' Mr. Patience joins TriSalus from Accelerate Diagnostics, where he served as CFO since 2023. He brings extensive experience in leading strategic product portfolio planning, in-depth market analysis of organic and in-organic portfolio opportunities and technical and commercial feasibility analysis of partnerships, mergers and acquisitions. Prior to his time at Accelerate, Mr. Patience held positions with Morgan Stanley's Investment Banking Division, Continental Advisors equity group, and various financial research roles at Nuveen Investments. Mr. Patience holds a Bachelor of Science in Business Administration from the University of Colorado Leeds School of Business and an M.B.A. from the University of Chicago Booth School of Business. About TriSalus TriSalus Life Sciences ® is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company's platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company's two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav ® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company's investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during early Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via the PEDD technology may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD technology are commonly present as well. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development. Forward Looking Statements Statements made in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company's PEDD drug delivery technology, TriNav ® system and nelitolimod investigational immunotherapy, and the Company's ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward-looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company's clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company's ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, and other risks described in the Company's filings with the Securities and Exchange Commission under the heading 'Risk Factors.' All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law.
Geek Girl Authority
5 days ago
- Entertainment
- Geek Girl Authority
TV Review: RESIDENT ALIEN Season 4
He's back, and this is, in fact, not some bullsh*t. Harry Vanderspeigle (Alan Tudyk) is having a terrible, horrible, no good, very bad day (as is his son, Bridget), but at least his misery is entertaining. When last we saw Harry in Resident Alien , he was stuck on the Greys' Moonbase, with the Mantid (also Tudyk) returning to Earth with Asta (Sara Tomko), D'arcy (Alice Wetterlund) and Ben/Kate's baby. Now, in Season 4, Harry must find a way to escape and defeat the alien impostor masquerading as him in Patience. Recently, I had the privilege of screening the first four episodes of Resident Alien Season 4. Does it pass muster? Does it exceed expectations? Read on for our spoiler-free review. RELATED: Geek Girl Authority Crush of the Week: Resident Alien 's Asta Twelvetrees About Resident Alien Season 4 RESIDENT ALIEN — 'Prisoners' Season 4 Episode 1 — Pictured: Corey Reynolds as Sheriff Mike Thompson — (Photo by: James Dittiger/USA Network) Here's a synopsis per Syfy: 'The fourth season starts with Harry (Tudyk) and his baby Bridget stuck in prison on the Grey Moonbase, while a shape-shifting Alien called a Mantid (also Tudyk) has taken over his body on Earth, passing himself off as the real Harry Vanderspeigle. Harry manages to escape the Greys and arrives back on Earth for a showdown with the Mantid Alien, but soon finds he may not have what he needs to finish the job. Asta (Tomko) and D'arcy (Wetterlund) struggle to keep a secret from Ben (Levi Fiehler) and Kate (Meredith Garretson), who are both desperate to find answers to what has been happening to them. Sheriff Mike (Corey Reynolds) and Deputy Liv (Elizabeth Bowen) attempt to solve some mysterious deaths in Patience that Sheriff Mike is beginning to think aren't caused by anything human.' Season 4 boasts a somewhat shaky start, with some storylines feeling rushed. Of course, the stakes are high. The Mantid is a formidable foe for our heroes and poses a significant threat to the people of Patience. As usual, though, the series tackles the Mantid issue with its signature quirkiness and wit. RELATED: 10 Out-of-This-World Predictions for Resident Alien Season 4 Performances RESIDENT ALIEN — 'Prisoners' Season 4 Episode 1 — Pictured: Sara Tomko as Asta Twelvetrees — (Photo by: James Dittiger/USA Network) Alan Tudyk knocks it out of the park, showcasing his versatility while playing Harry and the Mantid. He's still the comedic crux of Resident Alien . His scenes are always laugh-out-loud funny, and I'm someone who, while I watch more comedies than anything else, seldom laughs out loud. Tudyk is a slapstick aficionado — the king of physical comedy. He squeezes every drop out of a word, a line, even a glance. Nothing is wasted. If there's room for a laugh-inducing moment, Tudyk successfully swings for the fences. Corey Reynolds continues to kill it as Mike Thompson, the self-described 'no-nonsense' yet conspiracy theory-fueled sheriff who just had his own alien experience in the Season 3 finale. Reynolds walks that fine line between heightened comedy and realism. He knows how to make this over-the-top character, who could be merely comedic relief, feel grounded and honest. And the comedy blooms from that honesty. Alice Wetterlund shines in episode three, in particular, especially when opposite Tudyk. D'arcy is at her comedic best when focused on a mission, and she gets a lot of fun material in Season 4. Sara Tomko is still delightful as the 'straight man' character (and our human perspective) amid a roster of zany players, but she, too, stretches her comedic muscles this season. Not that Asta has never been funny; however, she doesn't fall squarely into that straight man category as much in Season 4. Tomko is at her funniest with Tudyk and/or Wetterlund. Those three are comedy dynamite together. RELATED: Read our Resident Alien recaps Enver Gjokaj plays off Tudyk well and gets his time in the limelight in episode two. He has fantastic comedic chops and should appear in more comedies if I have anything to say about it. Jenna Lamia is somehow even more hilarious as Judy this season, too. Finding Its Footing RESIDENT ALIEN — 'Prisoners' Season 4 Episode 1 — Pictured: (l-r) Levi Fiehler as Mayor Ben Hawthorne, Meredith Garretson as Kate Hawthorne — (Photo by: James Dittiger/USA Network) Circling back to my earlier remark about the rocky start, part of this is down to the initial separation of the cast. To me, this show is at its best when Harry interacts frequently with the human cast — his very alien demeanor bouncing off the springboard that is the more grounded characters. We get less of this in the first four episodes, along with pacing issues with certain arcs. However, Season 4 also introduces intriguing new storylines and, ultimately, begins finding its footing after a few episodes. These respective plots start to gel better further into the season and, after some bumps, everything flows with more ease. It also takes a beat to rediscover the show's heart and balance its trademark blend of humor and heart. Resident Alien Season 4 takes a hot minute to reorient itself and return to the hysterically heartfelt series we all love. Still, when it fires on all cylinders, it's truly, well, firing on all cylinders. Mind you, this is only having viewed episodes one through four. As with anything, there's room for improvement, and the new narrative threads are ripe with potential. I can't wait to see where we go from here. Be sure to have pepperoni pizza (and your emotional support human bestie) on hand when Resident Alien Season 4 premieres on Friday, June 6, 2025, at 11 pm EST/PST on USA Network and Syfy. New episodes will be available to stream one week later on Peacock. Syfy Renews THE ARK for Season 3 Contact: [email protected] What I do: I'm GGA's Managing Editor, a Senior Contributor, and Press Coordinator. I manage, contribute, and coordinate. Sometimes all at once. Joking aside, I oversee day-to-day operations for GGA, write, edit, and assess interview opportunities/press events. Who I am: Before moving to Los Angeles after studying theater in college, I was born and raised in Amish country, Ohio. No, I am not Amish, even if I sometimes sport a modest bonnet. Bylines in: Tell-Tale TV, Culturess, Sideshow Collectibles, and inkMend on Medium. Critic: Rotten Tomatoes, CherryPicks, and the Hollywood Creative Alliance.
BBC News
20-05-2025
- Entertainment
- BBC News
Patience TV drama set to begin filming second series in York
A hit TV drama set in York is due to start filming its second series next earlier this year, Channel 4's Patience became the broadcaster's biggest drama of 2025 so far and averaged 4.2 million drama follows police archivist Patience Evans, a young autistic woman who brings her "unique insight into a series of perplexing cases".Alison Kee, the show's executive producer, said: "We're really delighted it has been recommissioned and obviously York is the big star of the show for us." The second series will run over eight episodes and will see the return of Ella Maisy Purvis as Patience Evans, Nathan Welsh as Det Sgt Jake Hunter and Mark Benton as Det Ch Insp Calvin actor Jessica Hynes will take on the role of new boss Det Insp Frankie Monroe and "roar through the streets of York on her motorbike", according to Ms landmarks including Clifford's Tower, the Shambles and York Minster will feature in the show again. Purvis, 21, previously described filming in York as "magical"."The response and popularity of series one was staggering, so I am beyond thrilled to dive back into the world of Patience," she said. The second series is set to be released in 2026, although a specific date is yet to be Kee added: "We're hoping the show will look bigger and better than before." Listen to highlights from North Yorkshire on BBC Sounds, catch up with the latest episode of Look North.
Tom's Guide
16-05-2025
- Entertainment
- Tom's Guide
HBO Max just dropped a teaser trailer for new Mark Ruffalo crime thriller, ‘Task' — and it looks like a must-watch
HBO Max has just dropped a teaser for 'Task,' a new crime show from Brad Ingelsby, the creator of 'Mare of Easttown.' Frankly, that in of itself should be enough to put 'Task' on your radar. 'Mare of Easttown' was rightly branded as appointment viewing back in 2021, and the HBO streaming service is poised to bring us back to Pennsylvania. This time, it's not a small-town murder investigation, nor is Kate Winslet in the frame; "Task" instead sees MCU star Mark Ruffalo helming an FBI task force and hunting down a violent gang. With Guns N' Roses' 'Patience' setting a somber tone, the 'Task' teaser trailer tees up an intriguing, murky tale. Ruffalo's FBI agent is to helm a new task force (comprised, as he notes, primarily of inexperienced officers) to find and thwart a crew of violent, masked home invaders who've already carried out hits on nine homes. There are snatches of family life, awkward conversations, and a quick taste of some of the action that's coming our way — on-foot chases, shootouts, and a car tumbling down a hill — too. And with that background sketched, we build up to Ruffalo's team sweeping a building, with him on one side of a door… and armed family man/home invasion crew leader (Tom Pelphrey) on the other. Is this teaser setting up a violent end for one of our leads? We'll have to wait and see. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. Looking forward to 'Task'? You won't have to wait too much longer to check it out; HBO Max has confirmed that Brad Ingelsby's crime series will debut on HBO and HBO Max in September (an exact release date has not been confirmed at the time of writing), and new episodes will air on a weekly basis. HBO has shared a logline for the series, but it doesn't give much more info away about the show. It reads: 'Set in the working class suburbs of Philadelphia, an FBI agent (Mark Ruffalo) heads a Task Force to put an end to a string of violent robberies led by an unsuspecting family man (Tom Pelphrey).' In addition to Ruffalo and Pelphrey, we know 'Task' also stars Emilia Jones, Jamie McShane, Sam Keeley, Thuso Mbedu, Fabien Frankel, Alison Oliver, Raúl Castillo, Silvia Dionicio, Phoebe Fox, and Martha Plimpton. Mireille Enos also has a recurring role in the series. Creator and writer Brad Ingelsby will also serve as 'Task' showrunner, and the series has been directed by Jeremiah Zagar and Salli Richardson-Whitfield. Need something new to watch while you wait for 'Task' to air? Be sure to check out our round-up of the best shows on HBO Max for tons more streaming recommendations. "Mare of Easttown" fans might also want to keep an eye out for Apple TV Plus' upcoming family thriller 'Echo Valley." The new movie was penned by Brad Ingelsby and stars Julianne Moore, Sydney Sweeney, and Domhnall Gleeson.
Yahoo
15-05-2025
- Entertainment
- Yahoo
York crime drama to return for second series - with BAFTA winning actress
A HIT crime drama, set in York, will be returning for a second series this year - with a new BAFTA winning actress joining the cast. Patience, a Channel 4 drama set in York which tells the story of a young woman with autism who works in the criminal records department for 'City of York Police'. The first series, which premiered on January 8 of this year, was the biggest drama of the year for Channel 4 – averaging 4.2 million viewers per episode – and has announced a return to screens with a new eight episode series. RECOMMENDED READING: The new series will see Patience, played by Ella Maisy Purvis, continue her work in the police but when a new boss, played by BAFTA winner Jessica Hynes, brings a new management style to the team, the two find it tricky to navigate. Ella Maisy Purvis, who plays Patience, said: "The response and popularity of Series 1 was staggering, so I am beyond thrilled to dive back into the world of Patience for a Series 2, especially because we have some brilliant new cases to crack. Buckle up!" BAFTA Jessica Hynes will be joining the cast of Patience (Image: Provided) Jessica Hynes added: 'I am thrilled to be joining the cast of Patience as DI Frankie Monroe – I hugely enjoyed the first series as a viewer and looking forward to joining the team for the second series to be in the middle of the action.' Love is also in the air in this series as Patience begins a relationship with a work colleague Elliot and the police department - all whilst the team solve crimes in iconic York locations, such as the Minster. Filming for the first series took place around York (Image: Dylan Connell) The second series will see the return of regular cast members Nathan Welsh as DS Jake Hunter, Mark Benton as Calvin Baxter, Adrian Rawlins as Douglas Gilmore, Ali Ariaie as DC Will Akbari, Connor Curren as Billy Thompson, Liza Sadovy as Dr. Loretta Parsons and Tom Lewis as Elliot Scott. Jo McGrath, Chief Creative Officer at Eagle Eye Drama, says: 'We're so proud of Patience's success in the UK and the extended recommission is a real testament to the quality of our cast and talented crew, guided by our outstanding director Maarten Moerkerke. Series 2 promises to be even more action packed, culminating with a nail-biting hostage storyline and a shocking family revelation for Patience." The first series of Patience is still available to watch on the Channel 4 website.
